Bram Verstockt, ECCO-IBD 2022: Upadacitinib Transcriptional Changes in Ulcerative Colitis: Analysis of the U-ACHIEVE Study
It was a pleasure to talk with Dr. Bram Verstockt (KU Leuven, Leuven, Belgium) around his analysis of the U-ACHIEVE study, investigating transcriptional changes caused by upadacitinib in UC.
The abstract ‘Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE’ (Presentation no. OP30) was presented at the 17th Congress of ECCO, February 16-19, 2022!
QuestionsÂ
- What has the U-ACHIEVE study taught us about the efficacy and safety of upadacitinib in patients with moderately to severely active Ulcerative Colitis (UC)? (0:16)
- What was the rationale for the current analysis of U-ACHIEVE biopsy samples? (0:54)
- Could you tell us a little about the analyses that were undertaken and their findings? (1:29)
- What are the clinical implications of these findings? (3:00)
- Where do you see JAK inhibitors fitting into future treatment paradigms for UC? (3:59)
Disclosures: Bram Verstockt has received research support from Pfizer; speaker fees from Abbvie, Biogen, Bristol Myers Squibb, Chiesi, Falk, Ferring, Galapagos, Janssen, MondayNightIBD, MSD, Pfizer, R-Biopharm, Takeda and Truvion; and consultancy fees from Alimentiv, Applied Strategic, Atheneum, Bristol Myers Squibb, Galapagos, Guidepont, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
